TSI is a privately-held vascular medicine and biotechnology company currently developing a new-generation clot-dissolving therapy with the first novel mechanism of action in 20 years for stroke and other thrombotic diseases. TSI’s technology is based upon pioneering earlier work on pro-urokinase (proUK) by its cofounders. The primary component of TSI’s thrombolytic therapy is a rationally designed mutant of proUK.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Cambridge, Ma
- Phone
- 617-661-1103
- Industry
- Biotechnology
- Website
- tsillc.net
- HQ
- Cambridge, MA
Thrombolytic Science Questions
Thrombolytic Science's helpline number is 617-661-1103
Thrombolytic Science's website is tsillc.net
Thrombolytic Science's LinkedIn profile is https://www.linkedin.com/company/thrombolytic-science
Thrombolytic Science has
4 employees.
View email and phone details for 4
employees at Thrombolytic Science.
Thrombolytic Science's industry is
Biotechnology
Thrombolytic Science's top competitors are
Vaxess Technologies,
Viavi Labs,
Triform Sciences Llc,
Ventum Biotech,
Walden Biosciences,
Targeted Pharmaceuticals,
Whitelaw Compliance Group, Llc.,
Verve Therapeutics,
Tauriga Sciences Inc (Otcqb: Taug),
Tranquility Labs.
Thrombolytic Science's categories are Biotechnology
Thrombolytic Science's founding year is 2006
